Eukaryotic and prokaryotic organisms possess huge numbers of uncharacterized enzymes.
Selective inhibitors offer powerful probes for assigning functions to enzymes in native …

Abstract Parkinson's disease (PD), known as one of the most universal neurodegenerative
diseases, is a serious threat to the health of the elderly. The current treatment has been …

Leucine-rich repeat kinase 2 (LRRK2) is one of the most promising targets for Parkinson's
disease. LRRK2-targeting strategies have primarily focused on type 1 kinase inhibitors …

Mutations in Park8, encoding for the multidomain Leucine-rich repeat kinase 2 (LRRK2)
protein, comprise the predominant genetic cause of Parkinson's disease (PD). G2019S, the …

We previously reported that Parkinson's disease (PD) kinase LRRK2 phosphorylates a
subset of Rab GTPases on a conserved residue in their switch-II domains (Steger et al …

Mutations in leucine-rich repeat kinase 2 (LRRK2) are a common cause of familial
Parkinson's disease (PD) and a risk factor for the sporadic form. Increased kinase activity …

Over the past 15 years protein kinases have become the pharmaceutical industry's most
important class of drug target in the field of cancer. Some 20 drugs that target kinases have …

Propagation of α-synuclein aggregates has been suggested as a contributing factor in
Parkinson's disease (PD) progression. However, the molecular mechanisms underlying α …

Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of familial
and idiopathic Parkinson's disease. However, the mechanisms for activating its …

Chemical probes are critical tools for elucidating the biological functions of proteins and can
lead to new medicines for treating disease. The pharmacological validation of protein …